NMD Pharma A/S has announced top-line results showing its orally available ion channel inhibitor, NMD-670, has a positive clinical impact in myasthenia gravis (MG), with patients having stronger hand grip and improvements in quantitative MG scores.
CSPC NBP Pharmaceuticals Co. Ltd. entered an agreement that will grant it exclusive rights to Harbour Biomed Co. Ltd.’s anti-FcRn antibody, batoclimab (HBM-9161), in greater China, including Hong Kong, Macau and Taiwan.
Cabaletta Bio Inc. has announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain.
Finding a vaccine that provides universal protection against seasonal influenza remains a public health priority. Although influenza neuraminidase (NA) undergoes slower antigenic changes than hemagglutinin (HA) and therefore constitutes a desirable vaccine target, NA standalone vaccination strategies present a limited breadth of NA immunity.
Failure of integrin inhibitors in clinical trials can be avoided by redesigning the chemical conformation of these proteins, as shown by a study led by Timothy Springer, a professor in the Department of Biological Chemistry and Molecular Pharmacology at Boston Children's Hospital, and one of the winners of the 2022 Albert Lasker Basic Medical Research Award.
CEPI, the Coalition for Epidemic Preparedness Innovations, will provide seed funding of up to $4.8 million to Intravacc BV to advance the development of a broadly protective betacoronavirus vaccine candidate, which can be delivered intranasally.
Hanall Biopharma Co. Ltd. has clarified that the new FcRn inhibitor IMVT-1402, unveiled by its licensed partner Immunovant Inc. as a new development program for autoimmune diseases, is a compound discovered and developed by Hanall, HL-161ANS.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
Simcere Pharmaceutical Group has out-licensed its autoimmune drug candidate SIM-0278 for all indications to Almirall SA in a deal worth up to $507 million. Simcere granted exclusive global rights to the candidate to Almirall for development and commercialization excluding mainland China, Hong Kong, Macau, and Taiwan. In return, Almirall will pay Simcere $15 million up front.
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
RSS
